Literature DB >> 12242730

Differential expression of 17beta-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues.

Eitetsu Koh1, Toru Noda, Jiro Kanaya, Mikio Namiki.   

Abstract

BACKGROUND: The adrenal steroids dehydroepiandrosterone and androstenediones are converted into active androgen testosterone in prostatic tissues. Different 17beta-hydroxysteroid dehydrogenase (17betaHSD) isozymes are characterized by either oxidation or reduction reactions. These redox reactions represent an important step in both biosynthesis and metabolism of androgens. This study presents the differential expression of 17betaHSD isozyme genes in cancerous and noncancerous prostate tissues of in vivo samples.
METHODS: Thirty-four fresh specimens of transrectal prostatic needle biopsy were obtained; 11 were pathologically diagnosed as adenocarcinoma and 23 as without malignancy. The gene expression levels of five isozymes (type 1-5) of 17betaHSD were evaluated. The quantification of gene expression was assessed by means of the real-time polymerase chain reaction.
RESULTS: The expression levels of the type 3 17betaHSD gene with malignancy were significantly higher than those in prostatic tissues without malignancy, and those of type 2 17betaHSD with malignancy were significantly lower than those in nonmalignant tissues. There were no significant differences in 17betaHSD type 1, type 4, and type 5 gene expression in cancerous and noncancerous tissues.
CONCLUSION: Our results suggest that 17betaHSD type 2 and type 3 play an important role in the conversion of adrenal steroids into potential androgens in prostate cancer tissue. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12242730     DOI: 10.1002/pros.10139

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  18 in total

Review 1.  Regulation of 17β-hydroxysteroid dehydrogenases in cancer: regulating steroid receptor at pre-receptor stage.

Authors:  Mirja Rotinen; Joaquín Villar; Ignacio Encío
Journal:  J Physiol Biochem       Date:  2012-02-29       Impact factor: 4.158

Review 2.  Virtual screening applications in short-chain dehydrogenase/reductase research.

Authors:  Katharina R Beck; Teresa Kaserer; Daniela Schuster; Alex Odermatt
Journal:  J Steroid Biochem Mol Biol       Date:  2017-03-09       Impact factor: 4.292

3.  Tissue-specific transcription profiles of sex steroid biosynthesis enzymes and the androgen receptor.

Authors:  U Hoppe; P-M Holterhus; L Wünsch; D Jocham; T Drechsler; S Thiele; C Marschke; O Hiort
Journal:  J Mol Med (Berl)       Date:  2006-03-25       Impact factor: 4.599

4.  Substituted Aryl Benzylamines as Potent and Selective Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 3.

Authors:  Nigel Vicker; Helen V Bailey; Joanna M Day; Mary F Mahon; Andrew Smith; Helena J Tutill; Atul Purohit; Barry V L Potter
Journal:  Molecules       Date:  2021-11-26       Impact factor: 4.411

Review 5.  The basic biochemistry and molecular events of hormone therapy.

Authors:  Elahe A Mostaghel; Robert B Montgomery; Daniel W Lin
Journal:  Curr Urol Rep       Date:  2007-05       Impact factor: 3.092

Review 6.  Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications.

Authors:  Elahe A Mostaghel; Peter S Nelson
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-04       Impact factor: 4.690

Review 7.  Classical and Non-Classical Roles for Pre-Receptor Control of DHT Metabolism in Prostate Cancer Progression.

Authors:  Ailin Zhang; Jiawei Zhang; Stephen Plymate; Elahe A Mostaghel
Journal:  Horm Cancer       Date:  2016-01-21       Impact factor: 3.869

Review 8.  Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer.

Authors:  Philip A Watson; Vivek K Arora; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2015-11-13       Impact factor: 60.716

Review 9.  Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease.

Authors:  Elahe A Mostaghel; Bruce Montgomery; Peter S Nelson
Journal:  Urol Oncol       Date:  2009 May-Jun       Impact factor: 3.498

10.  11-Oxygenated androgen precursors are the preferred substrates for aldo-keto reductase 1C3 (AKR1C3): Implications for castration resistant prostate cancer.

Authors:  Monique Barnard; Jonathan L Quanson; Elahe Mostaghel; Elzette Pretorius; Jacky L Snoep; Karl-Heinz Storbeck
Journal:  J Steroid Biochem Mol Biol       Date:  2018-06-21       Impact factor: 4.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.